What Is BPC-157? Pentadecapeptide Structure, Proposed Mechanisms and Evidence Limits

BPC-157 is a fifteen-residue synthetic peptide with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, which the literature presents as a stable partial sequence of a protein present in human gastric juice. Among tissue-repair research peptides it has the largest body of published work — and it is also among the most exaggerated — so this guide keeps a strict separation between what studies report and what they do not. We supply research-grade BPC-157 as freeze-dried powder in sealed vials, for laboratory use only.

BPC-157 defined

"BPC" is short for body protection compound. The peptide is a fifteen-residue segment of a larger gastric-juice protein, and what distinguishes it in practice is how robust it is. Most short peptides are broken down quickly, but BPC-157 is reported to withstand degradation in human gastric juice for several hours — atypical behaviour that is the only reason oral and mucosal formats of it make any sense. "Pentadecapeptide" just means a peptide of fifteen residues.

An honest technical page needs one caveat up front. The protein from which BPC-157 supposedly derives is barely described in mainstream proteomics, and no endogenous receptor for the peptide has been identified. The fair characterisation is a synthetic sequence with reported biological effects, rather than a well-understood fragment of an established signalling pathway.

Origin and structure

• Sequence. Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val: fifteen residues, linear, with no disulfide bonds.
• Composition. There are four prolines in the chain and no cysteine, methionine or aromatic residues at all. Those prolines restrict how the chain can fold, which goes some way to explaining why proteases struggle with it; no methionine means one fewer oxidation risk; and with neither tyrosine nor tryptophan present, UV absorbance at 280 nm is negligible, so detection has to rely on the peptide bond itself at around 214 nm.
• Identifiers. CAS number 137525-51-0; molecular formula C62H98N16O22; molecular weight 1419.55 Da.
• Counter-ion. The acetate salt is the usual form, though arginate material is also sold; from the point of view of how much peptide a weighed sample really contains, the two are not the same material.

Proposed mechanisms of action

Because no specific receptor has ever been pinned down, every account of how this peptide works carries that qualification. Instead of a single pathway, the published work offers several that overlap:

• Angiogenesis. The theme reported most consistently: studies describe stronger VEGFR2 signalling and more new vessels in angiogenesis assays and in tissue models.
• A role for nitric oxide signalling. In a number of papers, the reported effects shift when NO synthase inhibitors or NO donors are present, which points to that system.
• Growth factors and fibroblasts. Reports of effects on how fibroblasts migrate, on collagen organisation, and on FAK–paxillin signalling in tendon-derived cells.
• Gut–brain axis and neurotransmitter systems. A smaller set of papers, largely from one laboratory, describes interactions with dopamine and serotonin systems.

That point about a single laboratory applies across the board. Much of the BPC-157 literature originates from one research group in Croatia. That does not invalidate the findings, but it does mean independent replications, where they exist, deserve extra weight. Our review of what BPC-157 has and has not been studied for goes into this in detail.

Research applications

• Gut models. Where the research began: rodent studies of damage to the stomach and intestinal lining, models of inflammatory bowel disease, and fistula healing.
• Tendon, ligament and muscle. Rodent studies of cut or injured tissue reporting quicker recovery, plus cell work on the migration of tendon fibroblasts.
• Vessels and organs. Work on the formation of new blood vessels, together with findings from various organ-injury models.
• Human evidence. There is no substantial body of published human trials. A few early-phase studies have been registered, but peer-reviewed outcome data in people are practically non-existent; every well-known claim about this peptide traces back to rodent or cell work.

Anyone planning work on the basis of these papers should first recognise how the rodent studies are typically designed. Most create an acute injury — a cut tendon, an induced lesion, a chemically damaged mucosa — and then compare treated with untreated tissue at a fixed time point. That design is well suited to spotting faster progress in a repair process that is already running, which is what those studies set out to test. It tells you much less about tissue that is not in active repair, and that is exactly the scenario most extrapolations have in mind. When you assess any BPC-157 claim, the first questions are which model produced it and how closely that model matches the situation it is being applied to.

Available formats

As well as injectable vials, BPC-157 is available in capsules, sublingual troches, nasal spray and cream, and in blends — with TB-500, and with KPV, for example. It is the peptide's unusual stability in gastric juice that makes the oral formats plausible at all. Everything is grouped in the tissue repair peptides collection.

A note on the administration route in preclinical work. Rodent studies have used intraperitoneal, intragastric and topical delivery, and the reported outcomes vary with route. Because of the claimed gastric stability, intragastric experiments are far more common than usual for a peptide of this size, and several papers compare routes head to head. Always report the route together with the effect. An outcome seen after intragastric dosing in rats is not evidence that another route gives the same result — and conflating the two is one of the commonest errors in secondary write-ups of this field, an error that multiplies quickly once a claim is detached from its source paper.

Reconstitution and storage at the bench

The arithmetic is routine bench work. Dissolve a 10 mg vial in 2 mL of bacteriostatic water and the concentration is 5 mg/mL, i.e. 5,000 mcg/mL; each 0.1 mL then contains 500 mcg. BPC-157 is forgiving to prepare — it is small, dissolves readily in water and has no disulfide bridges or easily oxidised residues — which is one reason labs starting out with peptides often choose it first.

Store unopened freeze-dried vials at −20 °C, dry and dark. Hold the reconstituted solution at 2–8 °C and use it up within the study. Split it into aliquots when you reconstitute, so the stock is not subjected to repeated freeze-thaw cycles. Our reconstitution guide has the details.

Purity and reading the certificate of analysis

Look for these on the certificate: an HPLC trace with the main peak's area percentage, a mass-spec identity result compared with the theoretical 1419.55 Da, net peptide content, the lot number and the date of analysis. Two points are specific to BPC-157. The salt form matters, because acetate and arginate material contain different amounts of peptide per milligram; if the certificate gives neither the salt nor the net peptide content, you cannot know the real concentration of your solution. The detection wavelength matters too. With no aromatic residues, the peptide has to be monitored at around 214 nm; a trace recorded only at 280 nm would be nearly flat — a quick way to tell whether a certificate was produced for this molecule or lifted from a generic template. See how to read a COA.

Two more considerations affect how BPC-157 should be handled as a research subject. The first is analytical. Four prolines and no aromatic rings give an unexceptional chromatogram, and a deletion impurity missing one proline runs very close to the main peak. A high purity figure from a fast gradient is therefore less convincing than the same figure from a gradient long enough to resolve those near neighbours; the method is as important as the number. The second is evidential. So much secondary writing compresses rodent data into broad statements that any lab citing this peptide should return to the original papers and record the species, model, route and endpoint. That takes little time and marks the difference between a defensible description of what was observed and the repetition of a claim that has drifted away from its original context.

Regulatory position

No country has approved BPC-157 as a medicine. In the US, the FDA lists it among bulk drug substances that may not be used in compounding — a specific regulatory classification rather than a verdict on safety one way or the other. WADA also includes it on its prohibited list. Research-grade BPC-157 is sold as a laboratory reference chemical, for research use only and not for human consumption.

Related compounds and comparisons

By far the most frequent question is about combining it with TB-500; see BPC-157 vs TB-500 for that.

Matching catalogue section: Tissue Repair & Healing Peptides